Can a doctor increase Cosentyx (secukinumab) dose for severe plaque psoriasis?
Yes. Cosentyx dosing can be increased depending on the patient’s response, severity, and the specific psoriasis regimen being used. In clinical practice and prescribing guidance, dose escalation is typically handled by moving from the standard regimen to the higher, more frequent starting/maintenance approach for patients who do not get adequate control.
What dosing options are used if the standard regimen doesn’t work?
Cosentyx is commonly used with an induction schedule followed by maintenance dosing. For people with inadequate response, clinicians may increase dosing frequency or adjust the maintenance dose under medical supervision rather than switching abruptly. The exact “increase” depends on how the patient is currently dosed and how their psoriasis is responding.
When is dose escalation usually considered?
Dose escalation is usually considered when severe plaque psoriasis does not achieve sufficient improvement after the induction period (or after an appropriate trial at the prescribed maintenance dose). Clinicians also consider factors like:
- Severity and extent of skin disease
- Prior treatment response (including biologics/phototherapy/systemic agents)
- Presence of psoriatic arthritis and overall inflammatory burden
- Safety signals (infections or other adverse effects)
What risks come with higher dosing?
Increasing biologic dosing can raise the likelihood of side effects. With secukinumab, the main safety concerns to monitor include infections (because it modulates immune signaling) and any treatment-related adverse effects. Any dose change should be paired with clinical monitoring and reassessment of benefit versus risk.
How does Cosentyx dose escalation compare with switching biologics?
If a higher Cosentyx regimen still does not control symptoms adequately, clinicians often consider switching to a different class of systemic therapy rather than continuing to escalate indefinitely. The best next step depends on:
- Degree of response to secukinumab so far
- Risk tolerance and comorbidities
- Drug access and prior authorization requirements
What should patients ask their prescriber?
Patients can ask:
- “Which Cosentyx dosing schedule am I on now, and would you increase frequency or maintenance dose?”
- “How long should we wait to judge response before changing dose?”
- “What safety monitoring do you want while we’re at the higher dose?”
- “If escalation fails, what is the next treatment option?”
Sources cited are not provided here because the question requires prescribing-specific dosing detail, and no provided source material was included in the prompt. If you share the exact Cosentyx psoriasis dosing schedule you’re currently using (starter vs maintenance, and any recent changes), I can help interpret whether your situation aligns with a dose-escalation approach.